Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.58 |
| ▸ | PRKCA | P17252 | 6/20 | 0.58 |
| ▸ | CDK2 | P24941 | 3/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | STK16 | O75716 | 1/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPK4 | P31152 | 1/20 | 0.56 |
| ▸ | TTK | P33981 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | CLK3 | P49761 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | CDK7 | P50613 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079465 | 0.89 | GSK3B (0.64) | GSK3BPRKCACDK2PRKCBPRKCH | |
| SCHEMBL4421134 | 0.80 | GSK3B (0.76) | GSK3BPRKCACDK2PLK4AURKA | |
| SCHEMBL27482282 | 0.78 | GSK3B (0.39) | GSK3BPRKCACDK2PLK4AURKA | |
| SCHEMBL4421751 | 0.75 | GSK3B (0.61) | GSK3BPRKCACDK2PLK4AURKA | |
| SCHEMBL6586180 | 0.75 | GSK3B (0.69) | GSK3BPRKCACDK2PRKCBPRKCE | |
| Hydrochloric Acid SCHEMBL6582692 | 0.74 | GSK3B (0.67) | GSK3BPRKCACDK2PRKCBPRKCE | |
| SCHEMBL20387052 | 0.73 | GSK3B (0.72) | GSK3BPRKCACDK2PLK4AURKA | |
| SCHEMBL13956706 | 0.72 | GSK3B (0.88) | GSK3BPRKCACDK2PLK4AURKA | |
| SCHEMBL6586550 | 0.71 | GSK3B (0.73) | GSK3BPRKCACDK2PLK4AURKA | |
| SCHEMBL13956698 | 0.71 | GSK3B (1.00) | GSK3BPRKCACDK2PLK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| EP-1307447-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | GSK3B 1/4885PRKCA 62/4885CDK2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.